Dengue (Dengue Fever)

An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. DENGUE HEMORRHAGIC FEVER is a more virulent form of dengue.

Also Known As:

Networked: 3639 relevant articles (119 outcomes, 432 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Malaria
3.	Thrombocytopenia (Thrombopenia)
4.	Japanese Encephalitis
5.	Dengue Hemorrhagic Fever

Experts

1.	Harris, Eva: 32 articles (10/2015 - 08/2004)
2.	Vasudevan, Subhash G: 31 articles (09/2015 - 09/2002)
3.	Guzmán, María G: 29 articles (08/2015 - 04/2002)
4.	Simmons, Cameron P: 28 articles (12/2015 - 05/2007)
5.	Rothman, Alan L: 27 articles (09/2015 - 05/2002)
6.	Yoksan, Sutee: 27 articles (09/2015 - 01/2002)
7.	Farrar, Jeremy: 26 articles (06/2015 - 07/2002)
8.	Ooi, Eng Eong: 25 articles (12/2015 - 08/2005)
9.	Alvarez, Mayling: 24 articles (10/2014 - 03/2002)
10.	Hermida, Lisset: 23 articles (08/2015 - 08/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dengue:

1.	VaccinesIBA 01/01/2006 - "Safe and effective vaccines are available against most pathogenic flaviviruses and in recent years substantial progress has been made in developing vaccines against dengue. " 06/01/2012 - "The development of safe and effective vaccines has been hampered by the requirement of conferring complete protection against all four dengue serotypes and the lack of a convenient animal model. " 02/14/2012 - "Overall, these data highlight the immunogenic profile of DENVax, a novel candidate tetravalent dengue vaccine and the advantage of sharing a common attenuated genomic backbone among the DENVax monovalent vaccines that confer protection against homologous or heterologous virus challenge." 01/16/2014 - "While vaccines effective against a subset of serotypes may reduce morbidity and mortality, particular profiles could result in an increased number of cases due to immune enhancement and other peculiarities of dengue epidemiology. " 02/01/2009 - "Taken together these studies indicate that the RepliVAX technology shows promise for use in the development of vaccines that can be used to prevent dengue."
2.	Immunoglobulin M (IgM)IBA 07/01/2015 - "Combination of clinical findings and rapid NS1, IgM detection helped in confirming the diagnosis for appropriate management of dengue in children." 01/01/2011 - "Using a panel of well-characterized sera and a collection of retrospective samples obtained during the dengue epidemics that occurred in Belém, Brazil, between 2002 and 2009, a modified immunoglobulin M-specific capture enzyme-linked immunosorbent assay (Rapid-MAC-ELISA) was evaluated and compared with the "gold standard" MAC-ELISA, in order to assess the specificity, sensitivity, stability, reproducibility and cost-effectiveness of this new assay. " 12/01/2009 - "None of 87 patients who had positive results for dengue immunoglobulin M in the 2007 study group had maculopathy, whereas it was seen in 10% of the 2005 group (P = .002). " 01/01/2008 - "Comparison of PanBio dengue IgM ELISA assay with pentax dengue IgM particle agglutination assay to evaluate factors affecting false positive results." 12/01/1983 - "IgM-ELISA appeared to help differential diagnosis on JE from dengue even when the HI test did not give positive results."
3.	Immunoglobulin G (IgG)IBA 01/01/2015 - "The efficacy of the device was evaluated by performing dengue antibody IgG ELISA on 64 hospitalized patients suspected of dengue. " 10/01/2010 - "Three WNV nonreactive samples were positive in the dengue IgG ELISA test; one of these also displayed positive results for dengue virus in the mosaic biochip IIFT and reactivity in yellow fever virus IIFT. " 09/01/2014 - "In our study, the serum samples were both detected by self-prepared anti-WNV-IgG diagnostic ELISA kit and the FDA certified kits ,which are FOCUS West Nile Virus IgG Dxselect and Panbio Dengue IgG Capture ELISA kits. " 01/01/2014 - "This study aimed to evaluate the prevalence of serum IgG dengue in children in an Amazonian population, to assess the seroconversion rate in 12 months, and to estimate how many seropositive children had a prior clinical diagnosis of dengue. " 01/01/2011 - "In this study, we describe a cross sectional seroepidemiology study of dengue IgG seroprevalence in the Malaysian adult population. "
4.	AntigensIBA 01/01/2015 - "Significantly, this molecule identified as an inhibitor of dengue type 2 protease was also effective in inhibiting each one of the four serotypes of dengue viruses in infected cells in culture, based on analysis of viral antigen synthesis and infectious virus production. " 01/01/2015 - "Laboratory dengue diagnosis can be performed through virus isolation, genome and antigen detection and serological studies. " 02/01/2014 - "Paper-based ELISA (specific to serotype-2 dengue fever), which builds off of our previous studies and a revised previous ELISA procedure, owns multiple advantages: 1) high sensitivity (about 40 times higher than the current ELISA-based approaches, due to our therapeutic-based monoclonal antibody) and specificity (specific to dengue virus serotype-2 nonstructural protein-1 antigens); 2) tiny amount of sample and reagent used for single tests; 3) short operating duration (i.e., rapid diagnostic device); and, 4) inexpensiveness (appropriate for use in all developing and underdeveloped nations of the world). " 12/01/2013 - "Taken together, the results of this preclinical study well demonstrate the great potential of ChinDENV for further development as a dengue vaccine candidate, and this kind of chimeric flavivirus based on JE vaccine virus represents a powerful tool to deliver foreign antigens. " 01/01/2013 - "Human leukocyte antigen (HLA) alleles have been correlated with susceptibility or resistance to severe dengue; however, few immunogenetic studies have been performed in Latin American (LA) populations. "
5.	AntibodiesIBA 10/01/2001 - "Dengue 2 viruses passaged in BHK cells in the absence of a selecting antibody, shared a common amino acid (S) at E53, which differed from both wild type and neutralisation escape mutant virus populations at this position (P) and may have been responsible for a significant reduction in the ability of these "passage control" virus populations to be neutralised by both 6B2 and 10F2 antibodies." 10/01/1984 - "Peripheral blood mononuclear cells (PBMC) from humans without antibodies to dengue 2 virus lysed dengue 2 virus-infected Raji cells to a significantly greater degree than uninfected Raji cells. " 12/01/2015 - "Although antiviral drug and therapeutic antibodies for dengue remain a work in progress, these studies have produced some promising results and may have the potential to be future drugs. " 03/01/1986 - "The recognition of unique dengue isolates should allow the selection of reference strains and vaccine candidate strains which will induce antibodies that are equally effective in neutralizing viruses from all geographic areas." 11/01/2015 - "In this study, we describe the seroprevalence of dengue antibodies in febrile persons with suspected acute dengue in Barbados. "
6.	Neutralizing AntibodiesIBA 01/01/2015 - "A recent efficacy trial of the most advanced dengue vaccine candidate, demonstrated only partial protection against all four DENV serotypes, despite three subsequent immunizations and detection of measurable neutralizing antibodies to each serotype in most subjects. " 12/10/2015 - "The efficacy of the most advanced candidate vaccine against symptomatic dengue in general and DENV-2 in particular was much lower than expected, despite the ability of the vaccine to induce neutralizing antibody against all four DENV serotypes. " 12/01/2005 - "Neutralizing antibody titers to dengue 2 were significantly lower in YF-immune animals than in YF-naive monkeys and protection against challenge with wild-type dengue 2 virus was observed in only 2 of 11 YF-immune monkeys. " 06/01/2006 - "Currently, the plaque reduction neutralization test (PRNT) is the gold standard measure of dengue neutralizing antibody responses, but this test is limited by time-consuming performance. " 07/01/2015 - "Despite the presence of neutralizing antibodies, a moderate efficacy was recently reported in phase 2b and 3 trials of a dengue vaccine; a better understanding of neutralizing antibodies in polyclonal human sera is urgently needed.We"
7.	Chikungunya virus infectionIBA 02/01/2011 - "Recent events with the first cases of local transmission of chikungunya and dengue fever virus in southern France by Aedes albopictus, adding to the nuisance and potential vectors that can be encountered when traveling in tropical or sub-tropical countries, has shown the value of a reflection on the Personal protection against vectors (PPAV). " 01/01/2015 - "An improved odor bait for monitoring populations of Aedes aegypti-vectors of dengue and chikungunya viruses in Kenya." 12/01/2015 - "Studies on insecticide susceptibility of Aedes aegypti (Linn) and Aedes albopictus (Skuse) vectors of dengue and chikungunya in Andaman and Nicobar Islands, India." 09/01/2015 - "The study established that C21 attracticide was efficacious in the field conditions and has potential for use in surveillance and management of dengue and chikungunya mosquitoes." 09/01/2015 - "Control of Aedes aegypti and Ae. albopictus, the vectors of dengue and chikungunya, by using pheromone C21 with an insect growth regulator: Results of multicentric trials from 2007-12 in India."
8.	Dengue VaccinesIBA 10/01/2009 - "Accurate disease surveillance and carefully monitored clinical trials will provide essential evidence concerning the efficacy of candidate dengue vaccines, which will hopefully herald a new era in dengue disease prevention." 01/01/2013 - "For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered." 10/01/2010 - "In this review, we consider the issues impacting conduct and design of dengue vaccine trials with reference to the recently published World Health Organization "Guidelines for Conduct of Clinical Trials of Dengue Vaccines in Endemic Areas." We discuss logistic, scientific and ethical challenges concerning evaluation and introduction of dengue vaccines; these range from randomized trials that establish "proof of concept" of vaccine efficacy, to post-"proof of concept" trials, particularly demonstration projects likely to be required for licensure or for the introduction of an already licensed vaccine into public use. " 02/13/2008 - "Using data gathered from a contingent valuation survey, this study estimated the willingness to pay (WTP) for a single dengue fever vaccine and the household demand function for dengue vaccines. " 12/08/2003 - "Research felt to be key to future decision-making regarding dengue vaccine introduction include: disease surveillance studies, in-country vaccine trials or pilot projects, and studies on the economic burden of dengue and the cost-effectiveness of dengue vaccines. "
9.	InsecticidesIBA 09/01/2013 - "Efficacy of the recommended dosages of frequently used insecticides in space spraying and larviciding in dengue vector control programmes was also tested. " 09/01/2012 - "Physiological resistance of natural population of Aedes aegypti to insecticides contribute to the decreased efficacy of chemical control as a main control strategy during dengue outbreaks. " 01/01/2007 - "Evaluating the efficacy of two pyrethroid insecticides on Aedes aegypti, thereby providing useful information for decision-making in controlling dengue. " 06/01/2013 - "Continuous resistance monitoring should be conducted regularly to confirm the efficacy of insecticides for dengue control. " 11/01/2014 - "Introduction This study was conducted in Brazil and Colombia,where dengue is endemic and vector control programs use chemical insecticides. "
10.	Monoclonal AntibodiesIBA 06/01/2015 - "In this study, a highly sensitive and accurate rapid diagnostic test (RDT) was developed using anti-dengue NS1 monoclonal antibodies. " 03/01/2014 - "Previous studies have indicated most human monoclonal antibodies (HMAbs) from dengue patients are cross-reactive and poorly neutralizing. " 03/01/1990 - "In this study, the dengue virus non-structural protein NS3 was examined in passive protection studies with monoclonal antibodies prepared against NS3 of dengue 1 virus (Hawaiian). " 03/01/1990 - "Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus." 06/01/1987 - "Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies."

Therapies and Procedures

1.	Platelet Transfusion (Blood Platelet Transfusions) 10/01/2015 - "The study was aimed to assess the clinico-hematological parameters, and the requirement and need for platelet transfusion in children with dengue fever. " 07/01/2015 - "The present study was carried out in order to review platelet transfusion practices during the epidemic of dengue. " 09/01/2014 - "To analyze the direct costs of dengue illness and platelet transfusion in Brazil based on the World Health Organization (WHO) guidelines, we conducted a retrospective cross-sectional census study on hospitalized dengue patients in the public and private Brazilian health systems in Dourados City, Mato Grosso do Sul State, Brazil. " 07/01/2009 - "Prospective observational study of low thresholds for platelet transfusion in adult dengue patients." 10/01/2015 - "The indications for platelet transfusion in dengue fever are clearly defined in World Health Organization (WHO) guidelines (2011) for dengue fever, but physicians face practical difficulty in its implementation in an epidemic setting. "
2.	Tourniquets 12/01/2011 - "Previous studies in febrile Asian children have suggested that the combination of a positive tourniquet test (TT) and leucopenia can distinguish dengue from other febrile illnesses, but little data exists on the usefulness of these tests in adults or in the Americas. " 09/01/2013 - "In addition, the tourniquet test was demonstrated to be an indicator of dengue severity." 09/01/2013 - "A positive tourniquet test can be a valuable tool to support diagnosis of dengue where laboratory tests are not available. " 09/01/2013 - "Evaluation of the diagnostic value of the tourniquet test in predicting severe dengue cases in a population from Belo Horizonte, State of Minas Gerais, Brazil." 07/01/2013 - "The tourniquet test (TT) is a physical examination maneuver often performed on patients suspected of having dengue. "
3.	Blood Transfusion (Blood Transfusions) 05/01/2015 - "This case brings additional evidence that dengue is indeed transmissible by blood transfusion and clinical manifestations, although rare, do occur." 07/01/2008 - "Transfusion transmission should be considered in patients with dengue after blood transfusion." 06/01/2008 - "One patient who had blood transfusion-acquired dengue fever was highlighted. " 12/01/2006 - "Transfusion support to Dengue patients in a hospital based blood transfusion service in north India." 01/01/2014 - "Treatment of acute dengue fever is supportive, with either oral or intravenous rehydration for mild or moderate disease and use of intravenous fluids and blood transfusion for more severe cases. "
4.	Insecticide-Treated Bednets 01/01/2008 - "Insecticide-treated bednets (ITNs) are effective in preventing nocturnally transmitted vector-borne diseases, but their effect on diurnally active dengue vectors has never been studied. " 01/01/2008 - "Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti." 01/01/2008 - "Insecticide-treated bednets had an immediate effect on dengue vector populations after their introduction, and over the next 5-12 months, the presence of ITNs may have continued to affect vector populations and dengue transmission."
5.	Fluid Therapy (Oral Rehydration Therapy) 09/01/2013 - "No cure for dengue exists; treatment is limited to rehydration therapy, and with vector control strategies proving to be relatively ineffective, a vaccine is an urgent priority. " 10/01/2012 - "There are no specific anti-dengue drugs and treatment is basically supportive and consists of early recognition of complications and appropriate fluid therapy. " 05/01/2012 - "For patients with DSS and the 30% of non-shocked dengue patients who require intravenous fluid therapy, a range of solutions is available for plasma volume support. " 08/01/2006 - "The low sensitivity of classifying DHF could be due to failure to repeat the tests or physical examinations at the appropriate time, early intravenous fluid therapy, and lack of adequate resources in an epidemic situation and perhaps a considerable overlap of clinical manifestations in the different dengue entities. " 03/01/1992 - "Treatment of classic dengue fever is supportive, whereas urgent rehydration therapy is often required in more severe forms. "